HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Consumer Health Journey Still Short Of Destination

This article was originally published in The Pink Sheet

Executive Summary

Bayer says issues encountered after acquiring Merck & Co.’s consumer brands two years ago have meant slower growth than expected. But it suggests that’s not a precedent for its planned mega-merger with Monsanto.

You may also be interested in...



Bayer Reiterates Pharma Commitment Post-Monsanto, Plays Up Pipeline

German conglomerate says five recent launches led by Xarelto and Eylea are expected to bring in more than $11bn in peak sales, a 33% increase over previous projections. CEO Baumann pledges to make the investments needed to continue growing the pharma business.

Bayer's ClariSpray Brings Hint Of Familiar Brand To Nasal Allergy Space

ClariSpray is the same formulation as GSK Consumer Healthcare's Flonase Allergy Relief, but Bayer is not making all of the same claims because OTC Flonase for another year has exclusivity among OTC intranasal corticosteroids for eye-related allergy relief.

Bayer Leveraging Consumer Growth From Product Launches, More Shelf Space

Global consumer chief Erica Mann says OTC drug and nutritional product sales should increase during the current quarter as consumers' self-care focus turns to sunscreens and allergy treatments. Bayer plans around 30 consumer product launches later in the year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS123127

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel